Sector
PharmaceuticalsOpen
₹66.29Prev. Close
₹63.41Turnover(Lac.)
₹22.16Day's High
₹66.58Day's Low
₹6552 Week's High
₹11152 Week's Low
₹49.06Book Value
₹24.52Face Value
₹10Mkt Cap (₹ Cr.)
491.16P/E
88.71EPS
0.75Divi. Yield
010 Feb 2025
12:00 AM
Board Meeting
Agenda : Audited Result
5 Sep 2024
12:00 AM
AGM
Announcement Date: 05 Sep, 2024
5 Sep 2024
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 73.77 | 73.77 | 73.77 | 44.27 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 129.78 | 122.22 | 110.74 | 105.28 |
Net Worth | 203.55 | 195.99 | 184.51 | 149.55 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 16.46 | 20.34 | 31.04 | 30.03 |
yoy growth (%) | -19.06 | -34.47 | 3.35 | -43.71 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -8.57 | -7.75 | -15.81 | -14.62 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | 1.38 | 0.51 | 0.62 | 0.89 |
Depreciation | -3.43 | -3.44 | -0.66 | -0.63 |
Tax paid | 0 | 0.03 | 0.51 | -0.47 |
Working capital | -3.05 | -121.58 | 13.22 | -29.74 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -19.06 | -34.47 | 3.35 | -43.71 |
Op profit growth | -39.31 | -125.46 | -244.24 | -45.16 |
EBIT growth | -1.64 | 41.81 | -10.36 | 0.41 |
Net profit growth | 149.2 | -51.05 | 170.09 | -31.49 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 0 | 1.97 | 52.4 | 59.4 | 56.73 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 0 | 1.97 | 52.4 | 59.4 | 56.73 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 37.4 | 42.81 | 30.12 | 6.86 | 6.5 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,686.2 | 128.43 | 4,04,587.86 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,942 | 76.08 | 1,57,710.9 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,511.6 | 26.24 | 1,22,115.23 | 1,438.15 | 0.86 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,237.7 | 60.07 | 1,09,583.71 | 485 | 0.86 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,500 | 53.29 | 1,03,053.87 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director & CEO
Sunil Kumar Kalidindi
Non Executive Director
Leona Ambuja
Independent Non Exe. Director
Kalyan Vijay Sivalenka
Non-Exec & Non-Independent Dir
Suryanarayana Raju Nandyala
Non Executive Director
Krishna Yeachuri
Independent Director
Uma Garimella
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Megasoft Ltd
Summary
Megasoft Limited is a transnational intellectual property-driven, product-based technology company, which incorporated on 29th June 1999 and focused its expertise on the telecom sector. The Company provides telecom services throughout the globe under XIUS-bcgi and also offers Outsourcing, Off-shoring and back-office services to other product companies in the areas of Product Life Cycle Management (PLM) & and Application Development & Maintenance Services (ADMS) under the name and style of BlueAlly. Megasoft has strong product engineering and product development capacities with Capability Maturity Model (CMM) Level 5 certification and has operations in India, U.S., UK, Singapore, Malaysia and Germany. The Company had merged with Indus e solutions a public listed company in the year of 2000. After three years, in 2003, Megasoft had acquired MCI and made it as a wholly owned subsidiary company. Then, in the year 2004, XIUS India Ltd was merged with the company to undertake the telecom services, under this the company offers architects infrastructure and mobile solutions that are flexible, scalable and robust, clearing the way for mobile operators to rapidly deliver differentiated services to their customers and stay ahead of the competition. Megasoft made it footprint in Germany, acquired German IT Services Company-beam AG-that has sound knowledge of European telecom business in the year of 2005. After a year, in 2006, VisualSoft Technologies Limited, a leading software solution
Read More
What is the Megasoft Ltd share price today?
The Megasoft Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹66.58 today.
What is the Market Cap of Megasoft Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Megasoft Ltd is ₹491.16 Cr. as of 12 May ‘25
What is the PE and PB ratio of Megasoft Ltd?
The PE and PB ratios of Megasoft Ltd is 88.71 and 2.77 as of 12 May ‘25
What is the 52 Week High and Low of Megasoft Ltd?
The 52-week high/low is the highest and lowest price at which a Megasoft Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Megasoft Ltd is ₹49.06 and ₹111 as of 12 May ‘25
What is the CAGR of Megasoft Ltd?
Megasoft Ltd's CAGR for 5 Years at 65.74%, 3 Years at 11.78%, 1 Year at -0.46%, 6 Month at -17.99%, 3 Month at -16.72% and 1 Month at 12.55%.
What is the shareholding pattern of Megasoft Ltd?
The shareholding pattern of Megasoft Ltd is as follows:
Promoters - 35.07 %
Institutions - 0.13 %
Public - 64.79 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
